Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2025-06-18 Capital/Financing Update
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Hansa Biopharma intends to carry out directed share issue of approximately 10 million shares and has entered into non-binding terms with NovaQuest to restructure debt
Capital/Financing Update Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and announces the company's intention to carry out a "directed share issue of approximately 10 million shares" and a debt restructuring agreement. This action involves the issuance of new shares and changes to capital structure/financing. This aligns directly with the definition of Capital/Financing Update (CAP). Although it involves share issuance, the primary focus is the financing plan (share issue proceeds for operations/trials and debt restructuring), making CAP more specific than SHA (Share Issue/Capital Change) or POS (Transaction in Own Shares). It is not a formal regulatory filing like a 10-K or an earnings release (ER), but a specific corporate action announcement.
2025-06-18 English
Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency
Regulatory Filings Classification · 99% confidence The document is titled "PRESS RELEASE" and announces a planned organizational restructuring, workforce reduction, and projected cost savings. It is dated May 26, 2025. Crucially, it states: "This information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation." This language strongly suggests a mandatory regulatory disclosure concerning internal corporate actions that impact operations or financial outlook, but it is not a standard financial report (like 10-K, IR, or ER). Since it is a general corporate announcement mandated by regulation (MAR) that doesn't fit the specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2025-05-26 English
Hansa Biopharma planerar omstrukturering för att optimera resursfördelning och förbättra operationell effektivitet
Regulatory Filings Classification · 99% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a planned restructuring, including workforce reduction and expected annual savings (40-50 million SEK). It explicitly states that the information is being made public according to the EU Market Abuse Regulation (MAR) and provides contact information for IR and Corporate Affairs. This type of announcement, detailing significant internal operational changes, cost-saving measures, and management commentary, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full financial report (10-K, IR) or a transcript (CT), and it focuses on immediate operational/financial news rather than just a dividend (DIV) or management change (MANG), the most fitting category is Earnings Release (ER), as restructuring announcements often accompany or precede formal earnings reports to explain financial outlook and efficiency drives. Given the short length and press release format, it is not a comprehensive report, but a key announcement.
2025-05-26 Swedish
Notice to Annual General Meeting in Hansa Biopharma AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled 'Notice to Annual General Meeting in Hansa Biopharma AB (publ)' and details the date, time, location, procedures for participation (in person or by advance voting), the proposed agenda items (including election of directors, auditors, remuneration, and incentive programs), and proposals from the Nomination Committee and the Board regarding the meeting's resolutions. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2025-05-26 English
Kallelse till årsstämma i Hansa Biopharma AB (publ)
AGM Information Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and explicitly states "Kallelse till årsstämma i Hansa Biopharma AB (publ)" (Notice of Annual General Meeting in Hansa Biopharma AB (publ)). The text details the date, time, location of the meeting (June 25, 2025), registration procedures, voting rights, and presents the proposed agenda items, including elections for the board, auditor, remuneration, and proposals regarding incentive programs. This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). The closest matching category is AGM Information (AGM-R), which covers presentations and materials shared during the AGM. While this is the *notice* for the meeting, it serves as the primary material leading up to and defining the AGM, making AGM-R the most appropriate classification over a general Regulatory Filing (RNS) or Proxy Statement (PSI), as the focus is explicitly on convening the AGM.
2025-05-26 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport' (Interim Report) for the period 'Januari – mars 2025' (Q1 2025). It contains detailed financial statements, including a balance sheet/income statement summary, management commentary on business performance, clinical pipeline updates, and significant events. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-04-24 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.